PIK3CA and metastatic melanoma: Using a pan-class I PI3K inhibitor (buparlisib), Niessner et al. demonstrated diminished AKT activity, decreased cell growth and proliferation, and increased apoptosis in numerous metastatic melanoma cell lines with various mutational profiles.